Literature DB >> 15926009

Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects.

G Allais1, G Bussone, C De Lorenzo, O Mana, C Benedetto.   

Abstract

Patients suffering from menstrual migraine (MM) may be ideal candidates for an intermittent prophylaxis, usually termed short-term or mini-prophylaxis. It covers the whole period of vulnerability, e. g., the perimenstrual period, starting some days before the expected onset of MM attack. Theoretically MM attacks are an optimal target for drugs specifically developed for acute head pain. Unfortunately, due to their particular tendency to be longer, more intense and less responsive to analgesics, symptomatic approaches alone are not often able to completely control pain and its correlates. Many drugs have been proposed for short-term prophylaxis of MM. In this paper we analyse only non-steroidal anti-inflammatory drugs, coxibs and triptans (especially those with longer half-life, naratriptan and frovatriptan). Moreover, MM can be prevented by a variety of hormonal manipulations, including oral contraceptives, which may be administered with an extended-dosing strategy; oestrogen replacement therapy; antioestrogen agents (danazol, tamoxifen); gonadotropin-releasing hormone agonists followed by oestrogen add-back therapy. Finally, the use of some products, such as magnesium and phytoestrogens, that probably meet the requirements of those patients that appreciate a more "natural" approach, is discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15926009     DOI: 10.1007/s10072-005-0424-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  5 in total

1.  The pharmacological management of migraine, part 2: preventative therapy.

Authors:  George Demaagd
Journal:  P T       Date:  2008-08

2.  Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan.

Authors:  Gianni Allais; Gennaro Bussone; Gisella Airola; Paola Borgogno; Ilaria Castagnoli Gabellari; Cristina De Lorenzo; Elena Pavia; Chiara Benedetto
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

3.  Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study.

Authors:  Gianni Allais; Gennaro Bussone; Giovanni D'Andrea; Franca Moschiano; Florindo d'Onofrio; Fabio Valguarnera; Gian Camillo Manzoni; Licia Grazzi; Rita Allais; Chiara Benedetto; Giancarlo Acuto
Journal:  Cephalalgia       Date:  2010-07-26       Impact factor: 6.292

4.  Prophylaxis of migraine.

Authors:  Ivan Garza; Jerry W Swanson
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

5.  Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine.

Authors:  Mario Guidotti; Michela Mauri; Caterina Barrilà; Francesca Guidotti; Carlo Belloni
Journal:  J Headache Pain       Date:  2007-10-23       Impact factor: 7.277

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.